Skip to main content

Day: August 31, 2024

FuelPositive Closes Final Tranche of Private Placement

WINNIPEG, Manitoba and WATERLOO, Ontario, Aug. 31, 2024 (GLOBE NEWSWIRE) — FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (the “Company”) announces that it has closed a non-brokered private placement (the “Offering”) and has issued 8,925,055 units (each, a “Unit”) at a price of $0.055 per Unit for gross proceeds of $490,878.  Each “Unit” consists of one common share of the Company, and one common share purchase warrant exercisable at a price of $0.07 until August 29, 2029.  The Offering represents the final tranche of the placement previously announced by the Company on May 28, 2024. No finders’ fees or commissions were paid in connection with completion of the Offering.  All securities issued in connection with the Offering are subject to restrictions on resale until December 30, 2024 in accordance with applicable...

Continue reading

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2024 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTSAs of June 30, 2024, the total revenue of Junshi Biosciences was approximately RMB786 million during the first half of 2024, representing an increase of approximately 17% compared to 2023. The growth was mainly due to the approximately 11% increase in revenue from pharmaceutical products compared to 2023. In particular, the domestic sales revenue of our core product, TUOYI® (toripalimab), reached approximately RMB671 million, representing an increase of approximately 50%...

Continue reading

Medivolve Announces Management Changes

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve” or the “Company”) (OTC: MEDVF; FRA: 4NC) announces today that David Preiner has resigned from his position as president and chief executive officer of the Company, effective August 26, 2024. Mr. Preiner will continue to support the Company in his capacity as a consultant. The board and management thanks Preiner for his service and contributions and wish him well in his future endeavours. About Medivolve Medivolve is a Canadian healthcare technology company headquartered in Toronto, Canada. The Company’s mission is to improve health and lives by delivering world-class diagnostic solutions—starting with COVID-19—as well as to enable faster and better care to patients through innovative technology. Medivolve, through its subsidiaries, operates retail patient-care...

Continue reading

Victory Square Technologies Reports Q2 2024 Financial Results

Revenue for the six-months ended June 30, 2024 was $7,993,311, an increase of 46% compared to Q2, 2023 VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that gives investor access to a portfolio of 25+ innovative companies from around the world in a single stock, announces it has filed its Consolidated Financial Statements for the six-months ended June 30th, 2024 along with its Management Discussion and Analysis (MD&A). Company: Victory Square is a Venture Builder that provides investors a liquid way to invest in early-stage technology companies without buying a venture fund that requires accredited investor status or multi-year commitments.A diverse portfolio of 25+ innovative companies from around...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.